Select Page
Home » Catalent News » Catalent Appoints Jim Walter as Vice President of Operations for Oral and Specialty Delivery

Catalent Appoints Jim Walter as Vice President of Operations for Oral and Specialty Delivery

SOMERSET, N.J. – February 12, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the appointment of Jim Walter as Vice President of Operations for its Oral and Specialty Delivery business. Mr. Walter will have operational responsibility for five of the company’s facilities and will report directly to Jonathan Arnold, President of the business unit.

In the role, Mr. Walter will be based at the company’s Morrisville site in Research Triangle Park, North Carolina, which is one of the sites within his responsibility. Additionally, he will oversee operations at Woodstock, Illinois and Malvern, Pennsylvania in the U.S., as well as Swindon and Dartford in the U.K.

Mr. Walter joins Catalent from his most recent post as Senior Vice President of Operations and Engineering at Tinuum Group, where he managed its U.S. operations. Prior to this, he spent 23 years with Mallinckrodt covering a multitude of operational roles and ultimately, he served as its Vice President of Manufacturing and Facilities. Jim also served as a Commissioned Officer in the U.S. Navy. He holds a bachelor’s degree in math from the U.S. Naval Academy and is APICS-Certified in Production and Inventory Management.

I am delighted to welcome Jim to head up the operations for this important part of the Catalent business,” commented Mr. Arnold. “The experience that he brings will ensure that the company continues to grow while providing our customers with the most efficient and operationally superior services.”

Notes for Editors

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

 

More products. Better treatments. Reliably supplied.™